Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Neutropenia (Feb 2021)

Posted by Matt Breese on Feb 5, 2021

Find me on:

According to our recent payer coverage analysis for neutropenia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for neutropenia treatments shows that under the pharmacy benefit, about 43% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Neutropenia-1Q2021Data snapshot as of Q1 2021

Trends: In June 2020, the FDA approved Pfizer Inc.’s Nyvepria (pegfilgrastimapgf) to decrease the incidence of infection, as manifested by febrile neutropenia, in people with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.  

To read the full Reality Check on Neutropenia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing